(firstQuint)Efficacy Study of Rapamycin- vs.

 Zotarolimus-Eluting Stents to Reduce Coronary Restenosis.

 This prospective, randomized trial will compare the efficacy and safety of a Rapamycin plus Probucol-eluting stent with a polymer based Zotarolimus-eluting stent.

 Patients with symptomatic coronary artery disease without cardiogenic shock who will undergo coronary angiography and willing to participate in the trial will receive a loading dose of 600mg clopidogrel at least 2 hours before the procedure.

 They will be randomized to receive one of the above mentioned stents.

.

 Efficacy Study of Rapamycin- vs.

 Zotarolimus-Eluting Stents to Reduce Coronary Restenosis@highlight

The purpose of this trial is to evaluate the efficacy of Rapamycin- and Zotarolimus-Eluting stents for the reduction of Coronary Restenosis